A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
← catalyst calendarNCT06767683 · readout ≤ 680 d
Sponsored by Alkermes, Inc. (industry) · ALKS — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
256estimated
Sites
49
Countries
Australia, Belgium, Czechia +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-27 | actual | When the study began enrolling |
| Primary completion | Jun 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Narcolepsy Type 1
- Narcolepsy Type 2
- Idiopathic Hypersomnia
Interventions
- Drug: ALKS 2680, 4mg
- Drug: ALKS 2680, 6mg
- Drug: ALKS 2680, 8mg
- Drug: ALKS 2680, 10mg
- Drug: ALKS 2680, 14mg
- Drug: ALKS 2680, 18mg
Primary outcome
what the primary-completion date above is the date OFIncidence of Treatment-Emergent Adverse Events
measured Up to 100 Weeks
Permalink · ALKS's whole pipeline · Catalyst calendar · Every registered study · What changed